Results
At visit 1 in 1987 to 1989, there were 15 703 ARIC participants at risk of developing AAA, and 5778 of them attended the visit 5 ultrasound examination in 2011 to 2013. Demographic characteristics and cardiovascular risk factors at baseline are shown in Table 1 . Compared with those who did not attend the ultrasound screening, the ultrasound subsample had a healthier cardiovascular risk factor profile at baseline (Table 1) , as expected for a survival cohort after long follow-up.
From visit 1 through 2011, during a median of 22.5 years of follow-up, we identified 590 clinical AAA events during 310 448 person-years of follow-up, yielding a crude incidence rate of 1.90 (95% confidence interval [CI], 1.75-2.06) per 1000 person-years. In the ultrasound subsample, we identified 75 additional asymptomatic AAAs based on the visit 5 ultrasound examination. Of the 75 asymptomatic AAAs, 60 had a maximal diameter of 30 to 39 mm, 11 had a maximal diameter of 40 to 49 mm, and 4 had a maximal diameter of ≥50 mm.
Lifetime Risk of Clinical AAA
Conditional on survival to 45 years of age, the lifetime risk of clinical AAA in the whole ARIC cohort was 5.6% (95% CI, 4.8-6.1; Table 2) , with a higher risk in men (lifetime risk of 8.2%), whites (6.5%), current smokers (10.5%), and those in the top 2 tertiles of smoking pack-years (9.0% and 11.1%). The lifetime risk and incidence rate of AAA stratified by race, sex, visit 1 age, smoking status, and pack-years are shown in Tables 2 and 3, respectively. There was a dose-response or gradient relationship of AAA lifetime risk with smoking status and smoking pack-years in the entire cohort and in men, women, and whites. In blacks, current smokers only had a slightly greater risk than former smokers, and participants in pooled pack-year tertiles 2 and 3 had a similar risk to those in tertile 1. However, the lifetime risk in blacks stratified by sex and smoking status is less The values are given as mean±SD or percentage. AAA indicates abdominal aortic aneurysm; ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAD, peripheral arterial disease; and SBP, systolic blood pressure.
*Eligible for clinical AAA ascertainment. †Excluding clinical AAAs ascertained during the follow-up. ‡P value for comparison between the ultrasound subsample and participants who did not attend the ultrasound examination after adjustment for age, sex, and race. December 2016 interpretable because of the limited number of AAAs in these subgroups. Conditional on survival to 55 years of age, the lifetime risk (95% CI) of AAA by longitudinal smoking status from visit 1 through visit 4/3 was as follows: never smokers (1.4% [0.9-1.8]), quitters before visit 1 (4.1% [3.2-4.9]), recent quitters (6.6% [2.3-9.7%]), and continuous smokers (9.4% [7.1-10.9]). Those who had quit smoking after visit 1 for at least 3 to 8 years (ie, recent quitters) had a 29% lower AAA lifetime risk compared with continuous smokers but still had a higher risk than participants who quit smoking before visit 1.
The clinical AAAs in the primary analysis included AAAs with rupture or corrective procedures and medically documented, asymptomatic AAAs. Because estimates of the incidence rate and lifetime risk for more severe clinical cases are also potentially useful, we conducted a secondary analysis focusing on the symptomatic subgroup. After exclusion of asymptomatic hospital or the Centers for Medicare and Medicaid Services outpatient AAAs, 181 clinical AAAs with a rupture or medical intervention remained, yielding an incidence rate of 0.58 (95% CI, 0.50-0.67) per 1000 person-years and a lifetime risk of 1.6% (95% CI, 1.2-1.8). Among the 181 cases, 27 had ruptures and 175 had medical intervention, with 21 of them having both. The incidence rates (95% CI)/lifetime risks (95% CI) by major risk factor categories were as follows: women −0.19 (0.14-0.27)/0.6 (0.3-0.9), men −1.11 (0.94-1.30)/2. Table 3 and Table I in the online-only Data Supplement show the associations between visit 1 risk factors and incident clinical AAA. For age and smoking pack-years, we performed separate analyses for the first 10 years of follow-up and for >10 years of follow-up, as the proportional hazard assumption was violated when using the entire follow-up time but held for each period separately. In the basic adjustment model ( Table  I in the online-only Data Supplement), age, male sex, white race, current and former smoking, pack-years of smoking, hypertension, peripheral arterial disease, height, triglycerides, and low-density lipoprotein (LDL) or total cholesterol were positively associated with incident clinical AAA, whereas diabetes mellitus and high-density lipoprotein cholesterol were negatively associated with AAA. BMI and alcohol consumption were not associated with AAA (data not shown). With simultaneous adjustment (Table 3) , the associations remained significant for most risk factors except triglycerides. The hazard ratios for age and smoking pack-years were stronger for earlier follow-up (when the cohort was younger) than later follow-up. Among the risk factors identified, age, smoking status, and pack-years showed the strongest associations with AAA, with hazard ratios ≈3to 9-fold higher in the highest 
Associations Between Visit 1 Risk Factors and Risk of Clinical AAA

Associations Between Visit 1 Risk Factors and Risk of Asymptomatic AAA Detected by Ultrasound
Similar to the clinical AAA data, white race, male sex, smoking status and pack-years, greater height, and elevated LDL or total cholesterol at baseline were significantly and independently associated with the risk of asymptomatic AAA (Table 4 ). Baseline age, hypertension, peripheral arterial disease, diabetes mellitus, and high-density lipoprotein cholesterol were not significantly associated with the risk of asymptomatic AAA (Table 4 and Table II in the online-only Data Supplement). Compared with the lowest tertiles, the odds ratios were >5-fold for current smokers and those in the top tertile groups for height or smoking pack-years at baseline.
Associations Between Longitudinal Smoking Status and AAA Risk
There was a significant association between the risk of both clinical and asymptomatic AAA and longitudinal smoking /d) , HDL-C, LDL-C, triglycerides, hypertension, PAD, and diabetes mellitus; for total cholesterol and smoking status as risk factors, the association analysis did not adjust for LDL-C or smoking pack-years, respectively.
Table 3. Continued
Baseline Characteristics
Person-Years N AAA AAA Incidence (95% CI)* Hazard Ratio (95% CI)** status that was defined prospectively based on information obtained from visit 1 through visit 4, with the highest risk being for continuous smokers, followed by recent quitters and then quitters before visit 1 (P for trend <0.01; Table 5 ). The associations were independent of the other AAA risk factors and visit 1 smoking pack-years, which was associated with longitudinal smoking status and thus could confound the associations. Compared with never smokers, those who had quit smoking after visit 1 for at least 3 to 8 years (ie, recent quitters) still had ≈2.6to 3.5-fold greater risk for both clinical AAA and asymptomatic AAA in the next 15 years of followup, consistent with the lifetime risk data.
Discussion
In this population-based, longitudinal study for a median of 22.5 years, we reported AAA incidence; AAA lifetime risk; and quantified AAA lifetime risk by race, sex, smoking status/ pack-years, and longitudinal smoking status. To the best of our knowledge, this is the first study to report the AAA lifetime risk in a community-based cohort with long follow-up. We also identified independent associations of clinical AAA incidence and asymptomatic AAA prevalence with traditional cardiovascular risk factors, including longitudinal smoking status.
Lifetime risk estimates are useful indicators of the public health burden of diseases in a population and various subgroups and thus are informative in guiding preventive and screening strategies. 16 Lifetime risk estimates are also helpful in patient consultation and in improving public awareness of disease conditions because they are more readily understood by the general public than standard epidemiological risk information (eg, incidence rate). 16, 17 The lifetime risk of AAA in our study was 1 in 17 and was higher in men (1 in 12), whites (1 in 15), current smokers (1 in 9), and those in the highest tertile of smoking pack-years (1 in 9). Although the lifetime risk of AAA is lower than that of the major cardiovascular diseases such as coronary heart disease (1 in 2-3) 18 and stroke (1 in 5-6), 19 the lifetime risk of AAA in high-risk subgroups for AAA is similar to the lifetime risk of other chronic diseases such as breast cancer (1 in 8 females) 20 and venous thromboembolism (1 in 12). 21 There has been only one previous report of AAA lifetime risk that was based on electronic health records in England, with a median of 5.5 years of follow-up. That study reported a lifetime risk of AAA at 3.3%, 1.3%, and 0.9% for current smokers, ex-smokers, and never smokers by age 90 years. 14 Smoking is the most important risk factor for AAA, as confirmed by prospective studies of clinical AAA [6] [7] [8] [9] 11, 14, 15 and asymptomatic AAA. 5 Compared with never smokers, current smokers in our study had a 6-to 7-fold greater risk of clinical AAA and ultrasound-detected asymptomatic AAA, and those in the highest tertile of smoking pack-years had >5-fold greater risk of ultrasound-detected asymptomatic AAA and 6to 25-fold greater risk of clinical AAA. The US Preventive Services Task Force recommends 1-time ultrasound screening for AAA in male ever smokers aged 65 to 75 years and selective screening in male never smokers aged 65 to 75 years. The US Preventive Services Task Force made no recommendation for screening in female ever smokers of this age group because of insufficient evidence on the benefits and harms of screening. Our study, based on a long follow-up, showed that the lifetime risk of clinical AAA in women who were current smokers (8.2%) was similar to men who were former smokers (8.1%) and higher than in men who were never smokers (3.9%). Our unique data on lifetime risk of AAA expands the previous report of an increased risk of AAA for women smokers during a median follow-up of 4.9 years 15 and another report of a higher incidence of AAA in women smokers than in men who never smoked during a mean of 12.7 years of follow-up. 22 These data may be useful to policy makers in considering preventive strategies for female smokers in the future. Our data also indicate that physicians may need to pay similar attention in monitoring female current smokers for the occurrence of AAA as to male ever smokers after they pass middle age. By all means, the best preventive strategy to reduce AAA risk in smokers is to stop smoking.
In addition, our longitudinal smoking data indicate that those who had quit smoking for at least 3 to 8 years (ie, recent quitters) still had an ≈2.6to 3.5-fold increased risk for both clinical AAA and asymptomatic AAA in the next 15 years compared with never smokers, and their lifetime risk of AAA (6.6%) was higher than longer term quitters (ie, quitters before visit 1) and never smokers (4.1% and 1.4%, respectively). The findings from our study add to the 3 previous studies that obtained smoking history at baseline and followed up participants for 5.5 years, 14 7 years, 5 and 16 years, 8 respectively. These studies reported a 2.6-to 6.5-fold increased risk for clinical or asymptomatic AAA for people who had quit smoking for <10 years. 5, 8, 14 To the best of our knowledge, there is no other study of AAA that quantified AAA risk, including lifetime risk, according to longitudinal smoking status.
Several prospective studies have assessed the associations between traditional cardiovascular risk factors and the risk of AAA. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, most of these studies focused on clinical cases without inclusion of asymptomatic AAA. [6] [7] [8] [9] [11] [12] [13] [14] [15] Although the overall risk factor profile for asymptomatic and clinical cases might be similar, the magnitude of associations could be different. Only 2 prospective studies specifically investigated asymptomatic AAA detected by ultrasound. 5, 10 The first identified 119 AAA cases from 4345 participants during 7 years of follow-up. 5 The second, including 35 cases and 140 controls, retrospectively investigated the relationship between asymptomatic AAA and lipids, which had been measured 12 years earlier. 10 Our study replicated the previously published positive associations of clinical AAA with age, male sex, white race, smoking status and pack-years, hypertension, peripheral arterial disease, height, and total or LDL cholesterol and negative associations with diabetes mellitus and high-density lipoprotein cholesterol. [6] [7] [8] [9] 11, [13] [14] [15] Our study also replicated associations of asymptomatic AAA with male sex, smoking status and pack-years, LDL and total cholesterol. 5,10 Among these, the identification of white versus black race and height as risk factors for ultrasound-detected, asymptomatic AAA is the first report for asymptomatic AAA from a prospective study. It is interesting to note that height showed a stronger association with asymptomatic AAA than clinical AAA in our study (risk ratio 6.37 versus 1.64 for tallest versus shortest tertiles), even though the distribution of baseline height in the ultrasound subset was similar to that of the whole ARIC cohort ( Table 1 ). The biological mechanism linking height to increased risk of AAA is unknown. In a meta-analysis of adult height with vascular morbidity and death, height was associated with increased risk of death from ruptured aortic aneurysm. 23 The authors postulated that the higher risk of rupturing associated with longer arteries might explain the association. 23 Nevertheless, future studies are needed to evaluate whether height predicts the risk of AAA using other AAA definitions based on an expected section of a patient's aorta according to height. We did not identify a significant association of alcohol consumption with either clinical or asymptomatic AAA, which agrees with some other studies. 5, 6, 9, 11 A study by Wong et al 8 reported a positive association between AAA and total alcohol consumption, but the association was attenuated after adjustment for hypertension. Another study by Stackelberg et al 12 found an inverse association between AAA and moderate consumption of alcohol, especially for consumption of beer in men and wine in women. Differences in sample size and beverage type might explain the discrepant findings across studies. Some limitations of this study warrant consideration. There might have been proportionately more undiagnosed AAAs in individuals who were lost to follow-up, resulting in an underestimated incidence, and thus lifetime risk, of AAA. In addition, the lifetime risk of AAA was approximated as the cumulative incidence of clinical AAA through 85 years of age. This approach might lead to an underestimation of lifetime risk of AAA because (1) AAA may present beyond 85 years of age and (2) asymptomatic AAAs detected by our one-time ultrasound screening were not included in the calculation of lifetime risk because of a lack of information about the time of onset. The issue of a lack of information about the time of onset also applies to clinical AAAs for which we used the time of clinical presentation or the time of diagnosis to calculate the incidence rate and lifetime risk. This constraint could only be addressed in a longitudinal study with multiple ultrasound screenings. The missingness of undiagnosed AAAs would likely have been nondifferential with regard to exposure level and thus likely diluted estimates of association between AAA and exposures. In the 2011 to 2013 ultrasound screening, the people who were evaluated had a healthier risk factor profile, which might have impacted the number of AAAs identified. In the analysis of asymptomatic AAAs with risk factors, we adjusted for the potential selection bias caused by differential participation in the ultrasound screening. Moreover, we defined hypertension and diabetes mellitus based on measurements of blood pressure and glucose or the use of corresponding medications. The risk of AAA might be different across treatment status and the extent of blood pressure or glucose normalization. Further studies are needed to evaluate whether treatment for hypertension and diabetes mellitus influences the risk of AAA. Finally, although we excluded participants with AAA repair before the baseline evaluation, we might have still included some prevalent AAAs in the cohort at baseline because of lack of a baseline ultrasound screening. However, the prevalence of AAA in the ARIC cohort at the baseline age of 45 to 64 years should have been low.
In conclusion, in this community-based prospective study with a long follow-up period, at least 1 in 17 middle-aged adults and 1 in 9 current smokers developed AAA in their lifetime, although the lifetime risk of rupture or medical intervention was lower. Those who had quit smoking for at least 3 to 8 years before follow-up started showed a 29% lower AAA lifetime risk compared with continuous smokers. In addition to smoking status and pack-years, several other cardiovascular risk variables measured in middle age, including white race, male sex, height, and LDL or total cholesterol, were associated with future risk for both clinical AAA and ultrasounddetected, asymptomatic AAA.
